Mean time to resistance to dacomitinib (Dacomitinib)

Dacomitinib (Dacomitinib), as a targeted therapy, often shows effective therapeutic effects in patients with EGFR (epidermal growth factor receptor) mutation-positive non-small cell lung cancer (NSCLC). However, over time, some patients may develop drug resistance, causing treatment to be less effective or ineffective.

Dacomitinib usually shows significant therapeutic effects in patients with EGFR mutation-positive NSCLC early in treatment. Most patients will observe significant tumor shrinkage or stabilization after starting treatment, resulting in improved survival and quality of life.

Despite significant initial efficacy, resistance to dacomitinib gradually emerged during treatment. Studies have shown that the average time to resistance is usually between 10 months and 18 months, meaning that most patients may experience disease progression or recurrence during this time.

The occurrence of drug resistance can be attributed to a variety of factors, including EGFR gene mutations (such as T790Mmutation), down-regulated receptor expression, changes in cell signal transduction pathways, and changes in other molecular mechanisms. These changes reduce the inhibitory effect of dacomitinib (dacomitinib) on tumor cells, leading to the development of drug resistance.

In response to resistance to dacomitinib, physicians may consider a variety of strategies to manage and prolong treatment effects. This includes adjusting the treatment plan, selecting other targeted drugs (such as osimertinib or nilotinib), or combining chemotherapy, radiotherapy and other comprehensive treatments to continue to inhibit tumor growth.

For each patient, doctors will develop an individualized treatment plan based on their condition and drug resistance. Regular clinical monitoring and evaluation are crucial to help doctors adjust treatment strategies in a timely manner to maximize treatment effects and improve survival rates.